Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
20.55 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 157.748 | 205.755 | 12.359 | 9.539 | 20.789 | 15.753 | 12.998 | 20.382 | 6.138 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 2.957 | 143.051 | 171.86 | 55.946 | 32.44 | 16.982 | 0.41 | 0.294 | 0.051 | 0 | 0 | 0 | 0 |
| Gross Profit
| 154.791 | 62.704 | -159.501 | -46.407 | -11.651 | -1.229 | 12.588 | 20.088 | 6.087 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.981 | 0.305 | -12.906 | -4.865 | -0.56 | -0.078 | 0.968 | 0.986 | 0.992 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 109.029 | 147.751 | 173.76 | 57.846 | 33.64 | 16.982 | 15.918 | 18.391 | 13.461 | 25.105 | 7.066 | 0.818 | 1.822 |
| General & Administrative Expenses
| 52.871 | 46.071 | 41.451 | 23.217 | 12.662 | 20.582 | 7.572 | 5.357 | 4.992 | 5.839 | 3.224 | 0.683 | 2.084 |
| Selling & Marketing Expenses
| -2.957 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 49.914 | 46.071 | 41.451 | 23.217 | 12.662 | 20.582 | 7.572 | 5.357 | 4.992 | 5.839 | 3.224 | 0.683 | 2.084 |
| Other Expenses
| 0 | -0.244 | 0 | 0 | 0 | 0 | -0.348 | 1.419 | 1.245 | 2.134 | 0 | 0 | 0 |
| Operating Expenses
| 158.943 | 193.578 | 215.211 | 81.063 | 46.302 | 37.564 | 23.49 | 25.167 | 19.698 | 33.078 | 10.29 | 1.501 | 3.906 |
| Operating Income
| -4.152 | 12.177 | -202.852 | -71.524 | -25.513 | -21.811 | -10.492 | -25.167 | -19.698 | -33.078 | -10.29 | -1.501 | -3.906 |
| Operating Income Ratio
| -0.026 | 0.059 | -16.413 | -7.498 | -1.227 | -1.385 | -0.807 | -1.235 | -3.209 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -23.738 | -1.533 | -0.822 | -0.624 | -0.478 | -0.302 | -0.348 | -1.419 | -1.245 | -2.134 | -0.197 | -0.015 | -0.023 |
| Income Before Tax
| -27.89 | 10.644 | -203.674 | -72.148 | -25.991 | -21.785 | -10.901 | -24.53 | -19.398 | -32.851 | -10.487 | -1.579 | -3.929 |
| Income Before Tax Ratio
| -0.177 | 0.052 | -16.48 | -7.563 | -1.25 | -1.383 | -0.839 | -1.204 | -3.16 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 1.835 | 1.295 | 3.189 | -0.784 | -0.27 | 0.212 | 0.001 | 0.073 | 0.051 | -0.017 | 0.061 | 0.065 | 0.021 |
| Net Income
| -29.725 | 9.349 | -206.863 | -71.364 | -25.721 | -21.785 | -10.902 | -24.603 | -19.449 | -32.834 | -10.548 | -1.579 | -3.929 |
| Net Income Ratio
| -0.188 | 0.045 | -16.738 | -7.481 | -1.237 | -1.383 | -0.839 | -1.207 | -3.169 | 0 | 0 | 0 | 0 |
| EPS
| -1.12 | 0.35 | -7.86 | -3.51 | -2.13 | -2.16 | -3.53 | -6.25 | -6.29 | -16.81 | -7.25 | -0.99 | -2.47 |
| EPS Diluted
| -1.12 | 0.35 | -7.86 | -3.51 | -2.13 | -2.16 | -3.53 | -6.25 | -6.29 | -16.81 | -7.25 | -0.99 | -2.47 |
| EBITDA
| -1.195 | 11.662 | -200.391 | -71.787 | -25.545 | -21.017 | -10.341 | -25.106 | -19.647 | -32.818 | -10.282 | -1.492 | -3.879 |
| EBITDA Ratio
| -0.008 | 0.057 | -16.214 | -7.526 | -1.229 | -1.334 | -0.796 | -1.232 | -3.201 | 0 | 0 | 0 | 0 |